eFoodSafety.com Inc. Completes Initial Steps in the Marketing and Distribution of Its Bird Flu Formula Citroxin.

SCOTTSDALE, Ariz. -- Patricia Gruden, president/CEO of eFoodSafety.com Inc. (OTCBB: EFSF), announced today that the company has entered into an agreement with Barry Ballow, Esq. The agreement provides for Ballow to seek interested qualified parties to forge strategic alliances with, and/or enter into distribution agreements with eFoodSafety.com Inc. to continue the commercialization of its proprietary patent pending formulations Citroxin and Citroxin O2. E[acute accent]Ballow is currently in various stages of discussion with potential interested parties. eFoodSafety.com Inc. selected Ballow because of his contacts with multibillion-dollar pharmaceutical and biotechnology companies. E[acute accent]The agreement with Ballow is solely performance based, and eFoodSafety.com Inc. feels very confident that Ballow can properly represent the products during his negotiations with pharmaceutical or biotechnology companies because of his years of experience in dealing with both individuals and companies. E[acute accent]Ballow stated, "My preliminary discussions with companies and/or individuals in the pharmaceutical and biotechnology arenas have been extremely positive to date. Prior to finalizing my agreement with eFoodSafety.com Inc., I did an abundance of due diligence on the products and its components. I feel very confident that I can properly represent the products in these areas, and I am very excited to have the opportunity."

E[acute accent]About eFoodSafety.com Inc.

E[acute accent]eFoodSafety.com Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also a distributor for Cinnergen(TM), a nonprescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has recently entered into a joint venture agreement with CK41 Direct Inc. to launch an anti-acne skin care system, with a branded name and celebrity spokesperson to be announced in the near future. E[acute accent]Please visit the company's Web site at: http://www.efoodsafety.com.

E[acute accent]Safe Harbor Forward-Looking Statements

E[acute accent]Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.